Table 1 The relationship between serum LDH, clinicopathological variables, weight loss, BMI, skeletal muscle mass, disease burden, systemic inflammation and survival in patients with advanced cancer, stratified by LDH (n = 436).
LDH < 250 Units/L (n = 110) | LDH 250–500 Units/L (n = 180) | LDH > 500 Units/L (n = 146) | P valuea | |
|---|---|---|---|---|
Age | 0.101 | |||
<65 | 48 (44) | 72 (40) | 57 (39) | |
65–74 | 38 (35) | 50 (28) | 39 (26) | |
>74 | 23 (21) | 58 (32) | 50 (34) | |
Sex | 0.412 | |||
Female | 52 (47) | 106 (58) | 78 (53) | |
Male | 58 (53) | 74 (41) | 68 (47) | |
Tumour site | 0.266 | |||
Lung | 51 (46) | 66 (37) | 45 (31) | |
GI | 20 (18) | 50 (28) | 54 (37) | |
Other | 39 (36) | 64 (35) | 47 (32) | |
Chemotherapy | 0.248 | |||
Yes | 61 (56) | 114 (63) | 92 (63) | |
No | 49 (44) | 66 (37) | 54 (37) | |
Radiotherapy | 0.427 | |||
Yes | 39 (35) | 80 (44) | 60 (41) | |
No | 71 (65) | 100 (56) | 86 (59) | |
Hormone therapy | 0.136 | |||
Yes | 13 (12) | 20 (11) | 26 (18) | |
No | 97 (88) | 160 (89) | 120 (82) | |
ECOG-PS | <0.001 | |||
0/1 | 69 (63) | 68 (38) | 43 (30) | |
2 | 30 (27) | 87 (48) | 62 (42) | |
3/4 | 11 (10) | 25 (14) | 41 (28) | |
Weight loss (>5%)b | 0.662 | |||
No | 70 (65) | 116 (67) | 96 (68) | |
Yes | 37 (35) | 57 (33) | 45 (32) | |
Low BMI | 0.273 | |||
No | 84 (76) | 109 (61) | 100 (68) | |
Yes | 26 (24) | 71 (39) | 46 (32) | |
Low skeletal muscle massc | 0.210 | |||
No | 33 (50) | 25 (46) | 22 (39) | |
Yes | 33 (50) | 29 (54) | 35 (61) | |
Metastatic disease | 0.118 | |||
No | 20 (18) | 44 (24) | 17 (12) | |
Yes | 90 (82) | 136 (76) | 129 (88) | |
NLR | 0.003 | |||
<3 | 43 (39) | 64 (35) | 44 (30) | |
3–5 | 31 (28) | 41 (23) | 20 (14) | |
>5 | 36 (33) | 75 (42) | 82 (56) | |
mGPS | 0.021 | |||
0 | 50 (45) | 77 (43) | 39 (27) | |
1 | 14 (13) | 38 (21) | 38 (26) | |
2 | 46 (42) | 65 (36) | 69 (47) | |
3-month survival | <0.001 | |||
Yes | 93 (93) | 121 (67) | 70 (47) | |
No | 17 (17) | 59 (33) | 76 (53) |
